- FDA NEWS RELEASE
For Immediate Release: July 17, 2012
Media Inquiries: Morgan Liscinsky, 301-796-0397; firstname.lastname@example.org
Consumer Inquiries: 888-INFO-FDA
FDA approves weight-management drug Qsymia
Vivus Inc. will be required to conduct 10 postmarketing requirements, including a long-term cardiovascular outcomes trial to assess the effect of Qsymia on the risk for major adverse cardiac events such as heart attack and stroke.
The most common side effects of Qsymia are tingling of hands and feet (paresthesia), dizziness, altered taste sensation, insomnia, constipation, and dry mouth.
Qsymia is marketed by Vivus Inc. in Mountain View, Calif.
For more information:
Approved Drugs: Questions and Answers1
FDA: Consumer Update - Medications Target Long-Term Weight Control2
CDC: Overweight and Obesity3
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.